<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cingulate Inc — News on 6ix</title>
<link>https://6ix.com/company/cingulate-inc</link>
<description>Latest news and press releases for Cingulate Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cingulate-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683555d178dffbe2df0e9782.webp</url>
<title>Cingulate Inc</title>
<link>https://6ix.com/company/cingulate-inc</link>
</image>
<item>
<title>Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS</description>
</item>
<item>
<title>Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-announces-closing-12-million-130000203</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-announces-closing-12-million-130000203</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”). “This long-term financing from life science–focused institutional investors represents strong validation of our strateg</description>
</item>
<item>
<title>EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement</title>
<link>https://6ix.com/company/cingulate-inc/news/euda-health-holdings-limited-announces-execution-of-securities-purchase-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/euda-health-holdings-limited-announces-execution-of-securities-purchase-agreement</guid>
<pubDate>Fri, 05 Dec 2025 14:30:00 GMT</pubDate>
<description>SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US$100,000. The Warrant is exercisab</description>
</item>
<item>
<title>Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-third-quarter-130000388</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-third-quarter-130000388</guid>
<pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
<description>Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Rece</description>
</item>
<item>
<title>Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-names-industry-veteran-bryan-130000829</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-names-industry-veteran-bryan-130000829</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-deliv</description>
</item>
<item>
<title>Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-presents-positive-phase-3-120000070</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-presents-positive-phase-3-120000070</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, announced today that the positive Phase 3 results from its pivotal trial of CTx-1301 (dex</description>
</item>
<item>
<title>Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-lead-adhd-candidate-ctx-204500805</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-lead-adhd-candidate-ctx-204500805</guid>
<pubDate>Thu, 23 Oct 2025 20:45:00 GMT</pubDate>
<description>Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom controlKANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that data from its lead ADHD candidate CTx-1301 (dexmethylphenidate</description>
</item>
<item>
<title>FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date</title>
<link>https://6ix.com/company/cingulate-inc/news/fda-accepts-cingulate-drug-application-120000570</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/fda-accepts-cingulate-drug-application-120000570</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY, Kan., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that the U.S. Food and Drug</description>
</item>
<item>
<title>Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-secures-exclusive-manufacturing-partnership-124500168</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-secures-exclusive-manufacturing-partnership-124500168</guid>
<pubDate>Wed, 17 Sep 2025 12:45:00 GMT</pubDate>
<description>Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-13</description>
</item>
<item>
<title>Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-second-quarter-124500795</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-second-quarter-124500795</guid>
<pubDate>Tue, 19 Aug 2025 12:45:00 GMT</pubDate>
<description>Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quart</description>
</item>
<item>
<title>Cingulate Provides Management Team Update</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-provides-management-team-130000494</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-provides-management-team-130000494</guid>
<pubDate>Fri, 15 Aug 2025 13:00:00 GMT</pubDate>
<description>Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate’s Chief Fi</description>
</item>
<item>
<title>Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-submits-drug-application-fda-124500613</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-submits-drug-application-fda-124500613</guid>
<pubDate>Wed, 06 Aug 2025 12:45:00 GMT</pubDate>
<description>Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patientsKANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U</description>
</item>
<item>
<title>Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-receives-4-3m-waiver-120000686</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-receives-4-3m-waiver-120000686</guid>
<pubDate>Tue, 29 Jul 2025 12:00:00 GMT</pubDate>
<description>PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee Act) fee waiver from the U.S. Food and Drug Administr</description>
</item>
<item>
<title>Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-appoints-nilay-patel-chief-120000929</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-appoints-nilay-patel-chief-120000929</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel’s appointment comes as Cingulate plans to sub</description>
</item>
<item>
<title>Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD</title>
<link>https://6ix.com/company/cingulate-inc/news/efficacy-results-announced-cingulate-phase-120000553</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/efficacy-results-announced-cingulate-phase-120000553</guid>
<pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
<description>Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “Unboxing Biotech” Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced the efficacy resul</description>
</item>
<item>
<title>FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301</title>
<link>https://6ix.com/company/cingulate-inc/news/fda-cingulate-aligned-filing-requirements-120000722</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/fda-cingulate-aligned-filing-requirements-120000722</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA)</description>
</item>
<item>
<title>Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-first-quarter-203000881</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-inc-reports-first-quarter-203000881</guid>
<pubDate>Thu, 08 May 2025 20:30:00 GMT</pubDate>
<description>Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financi</description>
</item>
<item>
<title>Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-announces-positive-top-line-120000878</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-announces-positive-top-line-120000878</guid>
<pubDate>Tue, 29 Apr 2025 12:00:00 GMT</pubDate>
<description>Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced positive top-line results from the CTx-1301-013 study, an FDA</description>
</item>
<item>
<title>Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-receives-3-million-grant-120000979</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-receives-3-million-grant-120000979</guid>
<pubDate>Wed, 09 Apr 2025 12:00:00 GMT</pubDate>
<description>CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Technology CTx-2103 has the Potential to Reduce Use of Benzodiazepine’s and Associated Withdrawal and Dependency Issues KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWI</description>
</item>
<item>
<title>Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301</title>
<link>https://6ix.com/company/cingulate-inc/news/cingulate-completes-pre-nda-meeting-120000674</link>
<guid isPermaLink="true">https://6ix.com/company/cingulate-inc/news/cingulate-completes-pre-nda-meeting-120000674</guid>
<pubDate>Thu, 03 Apr 2025 12:00:00 GMT</pubDate>
<description>NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) yesterday to discuss the submission of a new drug application (NDA) for its lead Phase 3 ass</description>
</item>
</channel>
</rss>